Our objective was to estimate the effects of the availability of transcatheter heart valve replacement (TAVR) on overall heart valve replacement volumes and aortic valve disease mortality over a long-term horizon. Our study uses the German healthcare system as a reference case, as it was among the first systems adopting TAVR therapy for routine care.
